Treatment with an anti-interleukin-23 antibody attenuated airway inflammation as well as fibrosis and reduced interleukin-17A and -22 levels in a murine model with the exacerbation of pulmonary fibrosis [187]. This evidence concerns the gene IL17A and pulmonary fibrosis.